Equities research analysts expect Albemarle Co. (NYSE:ALB) to announce earnings per share of $1.21 for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Albemarle’s earnings. The highest EPS estimate is $1.27 and the lowest is $1.17. Albemarle posted earnings of $0.78 per share in the same quarter last year, which indicates a positive year over year growth rate of 55.1%. The firm is scheduled to report its next earnings results on Monday, February 26th.

On average, analysts expect that Albemarle will report full year earnings of $4.47 per share for the current year, with EPS estimates ranging from $4.42 to $4.52. For the next year, analysts anticipate that the business will report earnings of $5.17 per share, with EPS estimates ranging from $4.90 to $5.40. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that that provide coverage for Albemarle.

Albemarle (NYSE:ALB) last issued its quarterly earnings results on Wednesday, November 8th. The specialty chemicals company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.01. The business had revenue of $755.00 million during the quarter, compared to analysts’ expectations of $732.19 million. Albemarle had a return on equity of 11.61% and a net margin of 30.07%. The firm’s revenue for the quarter was up 15.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.91 earnings per share.

Several equities research analysts recently issued reports on ALB shares. Loop Capital started coverage on Albemarle in a research note on Thursday, September 28th. They issued a “buy” rating and a $150.00 price target for the company. Royal Bank of Canada reiterated a “buy” rating and issued a $149.00 price target on shares of Albemarle in a research note on Wednesday, October 18th. Nomura boosted their price target on Albemarle from $146.00 to $154.00 and gave the company a “buy” rating in a research note on Tuesday, October 10th. Robert W. Baird reiterated a “hold” rating and issued a $135.00 price target on shares of Albemarle in a research note on Wednesday, November 1st. Finally, Oppenheimer upped their target price on Albemarle from $133.00 to $157.00 and gave the stock an “outperform” rating in a research note on Monday, October 16th. Eleven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Albemarle has an average rating of “Buy” and an average target price of $128.45.

Shares of Albemarle (NYSE ALB) opened at $131.79 on Thursday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.11 and a quick ratio of 1.56. The stock has a market capitalization of $14,560.00, a P/E ratio of 47.07, a P/E/G ratio of 1.68 and a beta of 1.69. Albemarle has a 12 month low of $86.98 and a 12 month high of $144.99.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, January 2nd. Shareholders of record on Friday, December 15th were paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.97%. The ex-dividend date was Thursday, December 14th. Albemarle’s payout ratio is presently 45.71%.

Several large investors have recently made changes to their positions in ALB. Schwab Charles Investment Management Inc. increased its holdings in shares of Albemarle by 0.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 496,880 shares of the specialty chemicals company’s stock worth $52,441,000 after buying an additional 1,504 shares in the last quarter. Blair William & Co. IL acquired a new position in shares of Albemarle during the second quarter worth $215,000. Pacer Advisors Inc. increased its holdings in shares of Albemarle by 9.0% during the second quarter. Pacer Advisors Inc. now owns 2,118 shares of the specialty chemicals company’s stock worth $224,000 after buying an additional 174 shares in the last quarter. Neuberger Berman Group LLC increased its holdings in shares of Albemarle by 43.5% during the second quarter. Neuberger Berman Group LLC now owns 13,701 shares of the specialty chemicals company’s stock worth $1,446,000 after buying an additional 4,154 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in shares of Albemarle during the second quarter worth $386,000. Institutional investors own 87.99% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Anticipate Albemarle Co. (ALB) Will Post Earnings of $1.21 Per Share” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/04/zacks-brokerages-anticipate-albemarle-co-alb-will-post-earnings-of-1-21-per-share.html.

About Albemarle

Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions.

Get a free copy of the Zacks research report on Albemarle (ALB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.